BOSTON, May 22, 2024 /PRNewswire/ -- According to the latest BCC Research study, the demand for the PEGylated Proteins Market is expected to grow from $10.2 billion in 2023 and is projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.
4% during the forecast period of 2023 to 2028. This report explores the current and future outlook of the PEGylated Proteins market and analyzes key drivers, restraints, and opportunities. It covers competitive dynamics, pipeline activities, and market forecasts for 2028.
Company profiles provide insight into business units, finances, products, and recent developments. The global market is segmented into North America, Europe, Asia Pacific, and Rest of the World. Historical data for 2020 and 2021 and forecasts for 2022 to 2028 are provided.
It should be noted that pEGylated vaccines are not included in the scope. Researchers are actively investigating the potential of site-specific PEGylation to increase the efficacy of protein drugs. Researchers aim to optimize drug delivery and prolong therapeutic activity by targeting specific sites on proteins.
In addition, there is a significant shift towards branched PEGylation, reflecting the increasing interest of the pharmaceutical industry in this approach. The focus on branched PEGylation is expected to drive the development and eventual launch of new products in this category. As researchers continue exploring innovative PEGylation technologies, protein-base.
